분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-03-23 13:01:09 , Hit : 945
 Using Gene Editing to Delete HIV from Human T Cells

GEN News Highlights

Mar 22, 2016

Researchers at Temple University used a CRISPR gene editing technique to remove HIV from the DNA of human cells grown in culture. Their study ("Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing") is published In Scientific Reports.

According to senior investigator on the new study, Kamel Khalili, Ph.D., Laura H. Carnell Professor and Chair of the Department of Neuroscience, Director of the Center for Neurovirology, and Director of the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM), "Antiretroviral drugs are very good at controlling HIV infection. But patients on antiretroviral therapy who stop taking the drugs suffer a rapid rebound in HIV replication." The presence of numerous copies of HIV weakens the immune system and eventually causes acquired immune deficiency syndrome, or AIDS.

Curing HIV/AIDS, which has claimed the lives of more than 25 million people since it was first discovered in the early 1980s, is the ultimate goal in HIV research. But eliminating the virus after it has become integrated into CD4+ T cells, the cells primarily infected with HIV, has proven difficult. Recent attempts have focused on intentionally reactivating HIV, aiming to stimulate a robust immune response capable of eradicating the virus from infected cells. However, to date, none of these "shock-and-kill" approaches has been successful.

Dr. Khalili and colleagues decided to try a different approach, specifically targeting HIV-1 proviral DNA using uniquely tailored gene editing technology. Their system includes a guide RNA that specifically locates HIV-1 DNA in the T cell genome, and a nuclease enzyme, which cuts the strands of T-cell DNA. Once the nuclease has edited out the HIV-1 DNA sequence, the loose ends of the genome are reunited by the cell's own DNA repair machinery.

In previous work, Dr. Khalili's team had demonstrated the ability of their technology to snip out HIV-1 DNA from human cell lines. In their latest study, however, they concentrated on latently and productively infected CD4+ T cells to show not only that the technology eliminates the virus from cells but also that its persistent presence in HIV-1–eradicated cells actually protects them against reinfection. More importantly, they carried their work over to ex vivo experiments in which T cells from patients infected with HIV were grown in cell culture, showing that treatment with the gene editing system can suppress viral replication and dramatically reduce viral load in patient cells.

In another major component of the study, Dr. Khalili's team addressed questions about off-target effects and toxicity. Using an approach known as ultra-deep whole-genome sequencing, which is considered the gold standard for genomic assessment, the researchers analyzed the genomes of HIV-1–eradicated cells for mutations in genes outside the region targeted by the guide RNA. Their analyses ruled out off-target effects on genes, including potential collateral effects on cellular gene expression. Studies of cell viability and proliferation showed that HIV-1–eradicated cells were growing and functioning normally.

"The findings are important on multiple levels," Dr. Khalili said. "They demonstrate the effectiveness of our gene editing system in eliminating HIV from the DNA of CD4 T cells and, by introducing mutations into the viral genome, permanently inactivating its replication. Further, they show that the system can protect cells from reinfection and that the technology is safe for the cells, with no toxic effects."

"These experiments had not been performed previously to this extent," he added. "But the questions they address are critical, and the results allow us to move ahead with this technology."








1207   Cancer Onset May Be Caused by Immune System Fighting Viruses  이성욱 2017/08/25 872
1206   Resistance to HIV Engineered Via CRISPR  이성욱 2017/08/07 880
1205   Zika Update  이성욱 2016/03/15 884
1204   [바이오토픽] 드디어 올 것이 왔다: CRISPR, 생존가능 인간배아의 질병초래 유전자 교정 성공  이성욱 2017/08/03 886
1203   “유전자 치료 법률 금지 한국 유일” vs “생명체 설계도 바꾸는 건 문제”  이성욱 2017/08/28 890
1202   CRISPR Corrects RNA-based Disease Defects  이성욱 2017/08/14 894
1201   [바이오토픽] 중국, 최초의 유전체편집 아기 탄생  이성욱 2018/11/27 904
1200   CRISPR Fixes Stem Cells Harboring Blindness-Causing Defect  이성욱 2016/02/01 907
1199   First In Vivo Human Genome Editing to Be Tested in New Clinical Trial  이성욱 2017/05/18 911
1198   [바이오토픽] FDA 자문위원회, CAR-T(chimeric antigen receptor T cell) 승인 만장일치로 권고  이성욱 2017/07/14 920
1197   ‘단세포 인공생명체’ 눈앞에 성큼  이성욱 2017/03/11 921
1196   유전자치료제 '인보사' 연골재생 입증못해도 허가받은 까닭  이성욱 2017/07/14 925
1195   CRISPR Can Tag RNA  이성욱 2016/03/26 930
1194   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 930
1193   Revisiting CAR T-Cells for Treating HIV Shows Promise  이성욱 2016/07/19 932
1192   독감바이러스의 ‘RNA 도둑질’  이성욱 2017/05/08 933
1191   RNA May Surpass DNA in Precision Medicine  이성욱 2016/03/23 938
1190   UPDATE 2-Gilead experimental drug fights all forms of hep C: data  이성욱 2015/09/24 940
1189   노벨 생리의학상 유감(有感)  이성욱 2015/10/06 940
1188   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 940

[1][2][3] 4 [5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN